Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Abundant filamentous tau inclusions in oligodendrocytes (OLGs) are hallmarks of neurodegenerative tauopathies, including sporadic corticobasal degeneration and hereditary frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). However, mechanisms of neurodegeneration in these tauopathies are unclear in part because of the lack of animal models for experimental analysis. We address this by generating transgenic (Tg) mice expressing human tau exclusively in OLGs using the 2′,3′-cyclic nucleotide 3′-phosphodiesterase promoter. Filamentous OLG tau inclusions developed in these Tg mice as a result of human tau expression in OLGs, especially those expressing the FTDP-17 human P301L mutant tau. Notably, structural disruption of myelin and axons preceded the emergence of thioflavin-S positive tau inclusions in OLGs, but impairments in axonal transport occurred even earlier, whereas motor deficits developed subsequently, especially in Tg mice with the highest tau expression levels. These data suggest that the accumulation of tau in OLG cause neurodegeneration, and we infer they do so by disrupting axonal transport. We suggest that similar defects may also occur in sporadic and hereditary human tauopathies with OLG tau pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 2×
“Discovery of pathogenic tau gene mutations in FTDP-17 provided compelling evidence that abnormalities of tau alone are sufficient to cause neurodegenerative disease (for review, see Forman et al., 2000; Lee et al., 2001; Higuchi et al., 2002b).”
BackgroundSelf-citationA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“…1994), mAb AT270 (1:1000 dilution) (Goedert et al., 1994), mAb 12E8 (1:1000 dilution) (Seubert et al., 1995), and rabbit polyclonal antibody T3P (1:250 dilution) (Lee et al., 1991) specific for phosphorylated tau; and mAb T1 specific for nonphosphorylated tau (1:500 dilution) (Binder et al., 1985).”
BackgroundSelf-citationMYELINATION IN RAT BRAIN: METHOD OF MYELIN ISOLATION1
Norton, W. T., & Poduslo, S. E. (1973) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1973.tb07519.x · Cited by 1,413 · cited 2×
“32 M sucrose as reported previously (Norton and Poduslo, 1973).”
MethodInfluentialLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996) · Nature · doi:10.1038/383550a0 · Cited by 1,036 · cited 1×
“…be observed in the PL Tg mice, but it remains to be determined whether tau phosphorylation occurs before aggregation and thereby enhances the polymerization of tau, or whether this occurs after tau has already assembled into fibrils (Goedert et al., 1996; Schneider et al., 1999; Geschwind, 2003).”
BackgroundDisruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination
Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P. E., Griffiths, I. R., & Nave, K.-A. (2003) · Nature Genetics · doi:10.1038/ng1095 · Cited by 1,036 · cited 4×
“phenotypes reflect aberrant neurodevelopment rather than neurodegenerative processes (Griffiths et al., 1998; Brady et al., 1999; Lappe-Siefke et al., 2003).”
BackgroundInfluentialBramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., & Lee, V. M. Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90057-x · Cited by 903 · cited 1×
“However, because tau phosphorylation negatively regulates the binding of tau to MTs (Drechsel et al., 1992; Biernat et al., 1993; Bramblett et al., 1993), this increase in the levels of free tau not bound to MTs may also facilitate tau fibrillization.”
BackgroundSelf-citationAxonal Swellings and Degeneration in Mice Lacking the Major Proteolipid of Myelin
Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M. H., Schneider, A., Zimmermann, F., McCulloch, M., Nadon, N., et al. (1998) · Science · doi:10.1126/science.280.5369.1610 · Cited by 889 · cited 4×
“phenotypes reflect aberrant neurodevelopment rather than neurodegenerative processes (Griffiths et al., 1998; Brady et al., 1999; Lappe-Siefke et al., 2003).”
BackgroundInfluentialInitiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879 · cited 1×
“…Tg tau at the lowest level, did not develop OLG tau inclusions, although they did so when they were crossbred with OLG-directed -synuclein Tg mice (Giasson et al., 2003), thereby implying that cofactors such as -synuclein, when expressed in OLG, can lower the threshold at which tau pathologies…”
BackgroundSelf-citationBiernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796
Cited by
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
“Although neurons are probably the most relevant cell type to study in relation to tauopathies, some tauopathies are associated with tau pathology in glial cells (Higuchi et al., 2005), and the proteins that interact with tau in different cell types likely overlap.”
BackgroundAnimal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676
“This was modelled in vivo by expressing P301L and WT human tau under the control of the 2′,3′-cyclic nucleotide 3′- phosphodiesterase and glial fibrillary acidic protein (GFAP) promoters, respectivel”
MethodMyelination and the trophic support of long axons
Nave, K.-A. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2797 · Cited by 648
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Kang, S. H., Li, Y., Fukaya, M., Lorenzini, I., Cleveland, D. W., Ostrow, L. W., Rothstein, J. D., & Bergles, D. E. (2013) · Nature Neuroscience · doi:10.1038/nn.3357 · Cited by 599
Metadata
- Authors
- Higuchi, M., Zhang, B., Forman, M. S., Yoshiyama, Y., Trojanowski, J. Q., & Lee, V. M.-Y.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2005-10-12
- Volume
- 25
- Issue
- 41
- Pages
- 9434-9443
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2010607678
- Cited by
- 127
- References
- 19
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies. https://app.cochat.ai/papers/10.1523/jneurosci.2691-05.2005
- The paper
- Higuchi, M., Zhang, B., Forman, M. S., Yoshiyama, Y., Trojanowski, J. Q., & Lee, V. M.-Y. (2005). Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.2691-05.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.